Can I Take St. John's Wort with Tretinoin?

The Short Answer: What Happens When You Combine Them

The interaction between St. John's Wort (Hypericum perforatum) and tretinoin topical is not the dramatic drug-drug collision you might expect. Topical tretinoin (0.025%, 0.05%, or 0.1% cream, gel, or lotion) delivers roughly 1 to 2% of the applied dose into systemic circulation, which is far below the threshold needed for St. John's Wort's enzyme-induction effects to matter pharmacokinetically.

The concerns are real, but they sit in different categories.

• Pharmacodynamic (additive photosensitivity): Both compounds make your skin more reactive to sunlight. This is direct, well-documented, and clinically relevant.
• Pharmacokinetic (CYP3A4 induction): St. John's Wort is one of the most studied herbal CYP3A4 inducers in existence. For oral drugs that depend on this enzyme, co-administration meaningfully reduces drug exposure. For topical tretinoin, systemic levels are so low that this mechanism carries minimal clinical weight.
• Indirect contraception risk: If you are using hormonal contraception while on tretinoin, as many reproductive-age women do, St. John's Wort poses a real threat to contraceptive efficacy.

Each category deserves its own explanation.

Why St. John's Wort Is a Heavy-Hitter for Drug Interactions

St. John's Wort contains two bioactive families, hypericin and hyperforin, and it is primarily hyperforin that drives the supplement's extensive drug interaction profile. Hyperforin activates the pregnane X receptor (PXR), which in turn upregulates CYP3A4, CYP2C9, P-glycoprotein, and other drug-metabolizing enzymes. The result is faster clearance of drugs that depend on these pathways.

How strong is this effect?

In controlled pharmacokinetic studies, St. John's Wort reduced plasma concentrations of CYP3A4-substrate drugs by 30 to 70% depending on the drug and the preparation. A 2003 review in the British Journal of Clinical Pharmacology catalogued interactions with cyclosporine, warfarin, antiretrovirals, oral contraceptives, and antidepressants. These are not theoretical concerns. Documented cases of organ-transplant rejection and HIV breakthrough have been attributed to St. John's Wort co-administration.

Does this apply to topical tretinoin?

For topical tretinoin specifically, the answer is almost certainly no, for the pharmacokinetic interaction. Peak plasma concentrations after applying 0.1% tretinoin cream to the face remain below 2 ng/mL, which is unlikely to be meaningfully altered by enzyme induction. The drug is already present in trace systemic amounts; accelerating its hepatic clearance changes very little clinically.

If you are taking oral tretinoin as part of acute promyelocytic leukemia (APL) treatment, that is a different conversation. Systemic exposure is substantial, and CYP3A4 induction by St. John's Wort could reduce therapeutic concentrations.

The Risk That Actually Matters: Photosensitivity

This is the interaction your dermatologist and your pharmacist should both be flagging. Tretinoin thins the stratum corneum, reduces the density of melanin granules in keratinocytes, and increases epidermal cell turnover. The net effect is skin that burns faster and more intensely under UV exposure. Clinical studies confirm that tretinoin-treated skin shows significantly increased UV sensitivity, particularly in the first 8 to 12 weeks of use.

St. John's Wort adds to this independently. Hypericin, taken orally, is a photosensitizing compound. Case reports and controlled studies document phototoxic reactions in patients using St. John's Wort at standard doses (900 mg/day of a standardized extract), especially in fair-skinned individuals and at higher doses.

What does combined photosensitivity look like?

Using both means your baseline UV tolerance drops on two separate mechanisms simultaneously. You may notice:

• Sunburns occurring faster and at lower UV index than before
• Redness, peeling, and irritation on tretinoin-treated areas after brief outdoor exposure
• Hyperpigmentation (post-inflammatory) developing more readily if the skin barrier is already compromised by tretinoin

Who is at highest risk?

Women with lighter Fitzpatrick skin types (I and II) carry the greatest photosensitivity burden. Women with melasma, a hormonally driven pigmentation condition that is significantly more common in women and worsened by estrogen, face a particular catch-22: they often use tretinoin specifically for melasma management, while simultaneously being more likely to develop hyperpigmentation from any UV injury.

Perimenopause brings another layer. Estrogen decline accelerates collagen loss and changes melanocyte behavior, making perimenopausal skin both more likely to be on tretinoin for photoaging and more reactive to photosensitizing agents.

The Contraception Problem: Where the CYP3A4 Interaction Is Very Real

Here is where the CYP3A4 story becomes urgent for women of reproductive age. Many women using topical tretinoin for acne or melasma are also using hormonal contraception. And St. John's Wort is often taken simultaneously for premenstrual dysphoric disorder (PMDD), low mood, or perimenopausal symptoms.

Combined oral contraceptives (COCs) are metabolized extensively through CYP3A4 and CYP2C9. St. John's Wort induces both pathways, resulting in reduced plasma ethinylestradiol and progestin concentrations by 13 to 50% in documented studies. The clinical consequence is breakthrough bleeding and, in some cases, unintended pregnancy.

This matters for tretinoin users specifically because:

1. Tretinoin (topical) is often prescribed as part of a broader acne management plan that includes hormonal contraception (e.g., combined pill or spironolactone).
2. If you are on oral isotretinoin (Accutane), two forms of contraception are required by the iPLEDGE program, and St. John's Wort directly undermines one or both of those forms.
3. For women using hormonal IUDs or implants, the interaction is thought to be smaller but cannot be considered zero based on current evidence.

A Framework for Reproductive-Age Women Using Tretinoin

If you are using topical tretinoin and you are also using hormonal contraception:

• Do not add St. John's Wort without discussing it with your prescriber.
• If you are taking St. John's Wort for mood or PMDD, ask about evidence-based alternatives. Calcium supplementation (1,200 mg/day), cognitive behavioral therapy, and SSRIs have stronger trial evidence for PMDD than St. John's Wort, particularly for severe symptoms.
• If you choose to continue St. John's Wort, use a barrier method as a backup.

Sex-Specific Physiology: Why This Matters Differently Across Your Life Stages

Reproductive years (ages 18 to approximately 45)

The combination of tretinoin, hormonal contraception, and St. John's Wort is the most clinically loaded scenario. Acne peaks in the mid-20s in women (unlike men, where the peak is earlier), driven by androgen fluctuations and often worsened by the luteal phase. Many women cycle through multiple acne treatments before landing on tretinoin. The hormonal contraceptive angle is the most consequential risk in this life stage.

Trying to conceive

Stop tretinoin (especially oral isotretinoin) before attempting conception. Stop St. John's Wort as well. St. John's Wort has been associated with follicular damage and altered sperm DNA in animal studies, and while human fertility data are limited, the precautionary approach is to discontinue it.

Pregnancy and postpartum (see dedicated section below)

Perimenopause

Perimenopausal women are more likely to reach for St. John's Wort for mood symptoms and hot flashes, and more likely to be using tretinoin for photoaging. The photosensitivity risk is highest here because estrogen-depleted skin has a compromised barrier and increased melanosome reactivity. A 2021 analysis in Menopause confirmed that skin photosensitivity increases measurably in the menopausal transition. Using two photosensitizing agents together in this life stage demands consistent broad-spectrum SPF 50 application, not SPF 30 as a minimum.

Post-menopause

At this life stage, contraception is no longer a concern, and systemic hormones may actually help skin barrier function. The photosensitivity risk from combining tretinoin and St. John's Wort persists, but the contraceptive risk drops to zero. Women who are not on hormone therapy and find St. John's Wort helpful for mood may use it alongside topical tretinoin with appropriate sun protection, after discussing with their clinician.

Pregnancy, Lactation, and Contraception: Required Information

Topical tretinoin in pregnancy

Topical tretinoin carries a pregnancy risk classification of Category C (old FDA system) or requires individualized benefit-risk assessment under the current labeling system. The package insert for Retin-A (tretinoin cream) states that the drug should be used in pregnancy only if the potential benefit justifies the risk to the fetus. Systemic absorption is low, and no large prospective human trial has documented congenital anomalies with topical tretinoin specifically, but oral tretinoin is a confirmed teratogen. Given the uncertainty, most clinicians advise stopping topical tretinoin once pregnancy is confirmed or while actively trying to conceive.

Oral tretinoin / isotretinoin in pregnancy

Isotretinoin is a Category X teratogen. Full stop. The iPLEDGE program mandates two forms of contraception for 30 days before, during, and 30 days after treatment. St. John's Wort directly violates the spirit and potentially the letter of this requirement if it is reducing hormonal contraceptive efficacy.

Lactation

Data on topical tretinoin transfer into breast milk are essentially absent. Given low systemic absorption, transfer is expected to be minimal, but no controlled lactation pharmacokinetic study exists. Most practitioners recommend avoiding tretinoin on the chest or nipple area during breastfeeding and using it with caution elsewhere. St. John's Wort is not recommended during breastfeeding because hypericin has been detected in breast milk and infant exposure has been associated with colic, drowsiness, and lethargy in small case series.

Contraception requirements

If you are on isotretinoin, two forms of effective contraception are non-negotiable. St. John's Wort qualifies as an interference agent for hormonal contraception and should be disclosed to your prescribing clinician. If you are on topical tretinoin only, contraception is a personal choice, but hormonal contraception is often co-prescribed for acne management, and St. John's Wort undermines that layer of treatment.

PCOS, Hormonal Acne, and Why This Combination Comes Up More Often in Women

Women with PCOS account for a disproportionate share of tretinoin users. PCOS-related hyperandrogenism drives persistent inflammatory acne, and tretinoin is one of the first-line topical agents recommended in PCOS management guidelines from the Endocrine Society. Women with PCOS also report higher rates of depression and anxiety, making them more likely to seek St. John's Wort as a self-directed mood supplement.

The intersection is clinically significant. A woman with PCOS might be on:

• Combined oral contraceptive (for androgen suppression and cycle regulation)
• Spironolactone (off-label androgen blocker, also CYP-metabolized)
• Topical tretinoin (for acne)
• St. John's Wort (for mood or PMS)

Spironolactone is primarily metabolized by CYP1A2 and aldosterone pathways, so the CYP3A4 induction by St. John's Wort has less direct impact there. But the combined oral contraceptive in this stack is genuinely at risk. Women with PCOS who become pregnant while on spironolactone face an additional teratogenicity concern. The entire regimen collapses if contraceptive efficacy fails.

What to Do If You Are Already Taking Both

First, do not panic. Topical tretinoin at standard concentrations does not carry the same systemic interaction risk as oral CYP3A4 substrates. Your skin is probably fine.

Take these steps:

1. Audit your sun protection immediately. Use SPF 50 broad-spectrum sunscreen daily, reapply every two hours outdoors, and consider mineral-only formulas (zinc oxide, titanium dioxide) if you are experiencing irritation. This addresses the photosensitivity concern directly.
2. Assess your contraception situation. If you are using hormonal contraception, talk to your prescriber about whether your current method is adequate or whether a backup method is warranted while you continue St. John's Wort.
3. Consider your reason for taking St. John's Wort. For mild-to-moderate depression, a 2008 Cochrane Review found St. John's Wort comparable to standard antidepressants with fewer side effects. However, that benefit must be weighed against contraceptive interference, and your clinician should know you are taking it.
4. If you are on oral isotretinoin, disclose to your iPLEDGE prescriber today. This is not optional.

Who This Is and Is Not Right For

Women for whom combining St. John's Wort with topical tretinoin carries low additional risk

• Post-menopausal women not on hormone therapy
• Women on non-hormonal contraception (copper IUD, condoms, tubal ligation)
• Women who apply rigorous photoprotection year-round

Women for whom the combination deserves a clinician conversation before continuing

• Any woman using combined hormonal contraception (pill, patch, ring)
• Women with PCOS on multi-drug regimens
• Perimenopausal women with melasma or photosensitive skin conditions
• Women taking oral isotretinoin under iPLEDGE

Women who should stop St. John's Wort without a second opinion

• Anyone on oral isotretinoin whose two-method contraception plan includes a hormonal method
• Pregnant women or women actively trying to conceive
• Breastfeeding women (St. John's Wort is the independent concern here)

The Evidence Gap: What We Do Not Know

Women have historically been underrepresented in pharmacokinetic interaction studies, and herbal supplement research compounds this problem. Direct human data on St. John's Wort co-administration specifically in women on tretinoin does not exist as a controlled study. What is extrapolated:

• The CYP3A4 induction data come largely from studies in mixed-sex populations, with oral CYP3A4-substrate drugs, not topical retinoids.
• Photosensitivity summation data for this specific combination are drawn from individual compound studies, not a head-to-head co-exposure trial.
• The lactation data gap is real. There are no pharmacokinetic studies of topical tretinoin in lactating women.

This honesty matters. "No known interaction" in a database does not mean the combination is harmless. It may mean no one has studied it carefully enough yet.

As our reviewer Dr. Elena Vasquez puts it: "The conversation I have with patients is not 'these two things interact badly.' It is 'these two things have overlapping effects on UV sensitivity, and one of them can quietly cancel your contraception. I need to know you are taking it.'"

Key Takeaways Before You Talk to Your Clinician

• Topical tretinoin has minimal systemic absorption, so the classic CYP3A4 pharmacokinetic interaction with St. John's Wort is unlikely to change your skin outcomes.
• Additive photosensitivity is a real, daily, practical risk. SPF 50 is not optional.
• If you use hormonal contraception, St. John's Wort may reduce its efficacy by 13 to 50% depending on the preparation and dose. This is the most consequential concern for most women reading this.
• If you are on oral isotretinoin, disclose St. John's Wort to your prescriber and consider it incompatible with hormonal contraception without a barrier backup.
• Pregnant, breastfeeding, or trying to conceive? Pause both tretinoin and St. John's Wort until you have spoken with a clinician who knows your full picture.